The U.S. Food and Drug Administration has approved the expansion of the use of the oral MS therapy Gilenya® (fingolimod, Novartis AG) to include the treatment of children and adolescents 10 years of age or older with relapsing MS. This is the first therapy specifically approved to treat pediatric MS

“The Society has been working on this issue for more than a decade, creating awareness and consistency around the diagnosis and care of children with MS,” said Cyndi Zagieboylo, President and CEO of the National MS Society. “We are a global leader in this field and are pleased to see the Society’s early and fundamental work helped lay the groundwork for this important breakthrough.”